At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

For the 10th consecutive day, the Israeli occupation military has continued its relentless aggression and invasion of Jenin, a city and refugee camp in the occupied West Bank. The assault has included ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

Klaus also said there was "no direct impact" on the agency's Lebanon operations from a new Israeli law banning UNRWA operations in East Jerusalem, the West Bank and the Gaza Strip and that "UNRWA ...

UNRWA Lebanon Says Not Impacted by US Aid Freeze or New Israeli Law By Emilie Madi BEIRUT (Reuters) - The director of the United Nations agency for Palestinian refugees in Lebanon said on ...

In case of abuse, Report this post. As widely expected, Israel did not withdraw from southern Lebanon on January 26. Under the 60-day ceasefire agreement, Israel was supposed to cede its positions ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...